Ray Dalio’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $65.9M | Buy |
111,169
+46,574
| +72% | +$23.2M | 0.29% | 61 |
|
|
2025
Q4 | $31.5M | Buy |
64,595
+48,530
| +302% | +$22.6M | 0.11% | 142 |
|
|
2025
Q3 | $6.73M | Sell |
16,065
-179,053
| -92% | -$60.2M | 0.03% | 420 |
|
|
2025
Q2 | $56.1M | Buy |
195,118
+1,334
| +0.7% | +$399K | 0.23% | 82 |
|
|
2025
Q1 | $59.7M | Buy |
193,784
+86,054
| +80% | +$29.5M | 0.28% | 79 |
|
|
2024
Q4 | $38M | Buy |
107,730
+45,975
| +74% | +$16.9M | 0.17% | 105 |
|
|
2024
Q3 | $22.1M | Buy |
61,755
+49,003
| +384% | +$16.6M | 0.13% | 145 |
|
|
2024
Q2 | $4.06M | Buy |
12,752
+4,802
| +60% | +$1.27M | 0.02% | 395 |
|
|
2024
Q1 | $1.83M | Sell |
7,950
-1,069
| -12% | -$241K | 0.01% | 509 |
|
|
2023
Q4 | $1.98M | Sell |
9,019
-9,128
| -50% | -$2.1M | 0.01% | 518 |
|
|
2023
Q3 | $4.1M | Sell |
18,147
-22,658
| -56% | -$5.22M | 0.02% | 387 |
|
|
2023
Q2 | $9.01M | Sell |
40,805
-460
| -1% | -$102K | 0.06% | 215 |
|
|
2023
Q1 | $9.24M | Buy |
41,265
+16,161
| +64% | +$3.98M | 0.06% | 214 |
|
|
2022
Q4 | $6.98M | Sell |
25,104
-19,113
| -43% | -$4.82M | 0.04% | 300 |
|
|
2022
Q3 | $9.26M | Sell |
44,217
-10,209
| -19% | -$2.28M | 0.05% | 264 |
|
|
2022
Q2 | $12.8M | Buy |
+54,426
| New | +$11.1M | 0.05% | 281 |
|
|
2019
Q2 | – | Sell |
-9,124
| Closed | -$1.07M | – | 366 |
|
|
2019
Q1 | $1.07M | Buy |
+9,124
| New | +$1.06M | 0.01% | 240 |
|
|
2018
Q4 | – | Sell |
-53,726
| Closed | -$6.87M | – | 517 |
|
|
2018
Q3 | $6.87M | Buy |
53,726
+8,401
| +19% | +$1.04M | 0.07% | 101 |
|
|
2018
Q2 | $5.13M | Sell |
45,325
-116,024
| -72% | -$12.8M | 0.05% | 134 |
|
|
2018
Q1 | $18.1M | Buy |
161,349
+67,626
| +72% | +$8.59M | 0.17% | 39 |
|
|
2017
Q4 | $13.9M | Buy |
93,723
+953
| +1% | +$121K | 0.11% | 38 |
|
|
2017
Q3 | $10.9M | Buy |
92,770
+18,802
| +25% | +$2.4M | 0.07% | 72 |
|
|
2017
Q2 | $9.6M | Buy |
73,968
+15,876
| +27% | +$1.98M | 0.09% | 59 |
|
|
2017
Q1 | $7.86M | Buy |
58,092
+14,187
| +32% | +$2.15M | 0.09% | 69 |
|
|
2016
Q4 | $6.3M | Sell |
43,905
-69,900
| -61% | -$8.92M | 0.06% | 116 |
|
|
2016
Q3 | $13.4M | Buy |
113,805
+49,705
| +78% | +$5.97M | 0.13% | 47 |
|
|
2016
Q2 | $6.79M | Sell |
64,100
-21,733
| -25% | -$2.42M | 0.09% | 92 |
|
|
2016
Q1 | $9.56M | Buy |
85,833
+57,672
| +205% | +$7.3M | 0.12% | 53 |
|
|
2015
Q4 | $4.41M | Buy |
+28,161
| New | +$4.1M | 0.06% | 129 |
|
Other funds holding UTHR
ACA
VPM
VCM
Ray Dalio's UTHR Position: Q1 2026 in Review
Ray Dalio increased its United Therapeutics (UTHR) stake by 72% in Q1 2026, buying an estimated $23.2M and bringing the position to 111,169 shares worth $65.9M. The position accounts for 0.29% of the portfolio, ranked #61.
Ray Dalio first reported a position in UTHR in Q4 2015 and has held it in 29 quarters since. 852 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Ray Dalio held 111,169 shares of United Therapeutics worth $65.9M as of Q1 2026.
- Ray Dalio bought 46,574 United Therapeutics shares in Q1 2026, an estimated $23.2M.
- United Therapeutics made up 0.29% of Ray Dalio's portfolio in Q1 2026, its #61 holding.
- Ray Dalio first reported a position in United Therapeutics in Q4 2015 and has held it in 29 quarters since.
- 852 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.